製品: Phospho-WASP (Tyr291) Antibody
カタログ: AF7304
タンパク質の説明: Rabbit polyclonal antibody to Phospho-WASP (Tyr291)
アプリケーション: WB IHC
Cited expt.: WB
反応性: Human, Mouse, Rat
予測: Sheep, Rabbit, Dog, Xenopus
分子量: 53kd; 53kD(Calculated).
ユニプロット: P42768
RRID: AB_2843744

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $350 在庫あり
 200ul $450 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Sheep(80%), Rabbit(100%), Dog(100%), Xenopus(100%)
クローナリティ:
Polyclonal
特異性:
Phospho-WASP (Tyr291) Antibody detects endogenous levels of WASP only when phosphorylated at Tyr291.
RRID:
AB_2843744
引用形式: Affinity Biosciences Cat# AF7304, RRID:AB_2843744.
コンジュゲート:
Unconjugated.
精製:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

Eczema thrombocytopenia; IMD2; SCNX; THC; THC1; Thrombocytopenia 1 (X linked); U42471; Was; WASp; WASP_HUMAN; Wiskott Aldrich syndrome (eczema thrombocytopenia); Wiskott Aldrich syndrome; Wiskott Aldrich syndrome protein; Wiskott-Aldrich syndrome protein;

免疫原

免疫原:

A synthesized peptide derived from human WASP around the phosphorylation site of Tyr291.

Uniprot:
遺伝子(ID):
発現特異性:
P42768 WASP_HUMAN:

Expressed predominantly in the thymus. Also found, to a much lesser extent, in the spleen.

タンパク質配列:
MSGGPMGGRPGGRGAPAVQQNIPSTLLQDHENQRLFEMLGRKCLTLATAVVQLYLALPPGAEHWTKEHCGAVCFVKDNPQKSYFIRLYGLQAGRLLWEQELYSQLVYSTPTPFFHTFAGDDCQAGLNFADEDEAQAFRALVQEKIQKRNQRQSGDRRQLPPPPTPANEERRGGLPPLPLHPGGDQGGPPVGPLSLGLATVDIQNPDITSSRYRGLPAPGPSPADKKRSGKKKISKADIGAPSGFKHVSHVGWDPQNGFDVNNLDPDLRSLFSRAGISEAQLTDAETSKLIYDFIEDQGGLEAVRQEMRRQEPLPPPPPPSRGGNQLPRPPIVGGNKGRSGPLPPVPLGIAPPPPTPRGPPPPGRGGPPPPPPPATGRSGPLPPPPPGAGGPPMPPPPPPPPPPPSSGNGPAPPPLPPALVPAGGLAPGGGRGALLDQIRQGIQLNKTPGAPESSALQPPPQSSEGLVGALMHVMQKRSRAIHSSDEGEDQAGDEDEDDEWDD

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Dog
100
Xenopus
100
Rabbit
100
Sheep
80
Pig
0
Horse
0
Bovine
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

機能:

Effector protein for Rho-type GTPases that regulates actin filament reorganization via its interaction with the Arp2/3 complex. Important for efficient actin polymerization. Possible regulator of lymphocyte and platelet function. Mediates actin filament reorganization and the formation of actin pedestals upon infection by pathogenic bacteria. In addition to its role in the cytoplasmic cytoskeleton, also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA. Promotes homologous recombination (HR) repair in response to DNA damage by promoting nuclear actin polymerization, leading to drive motility of double-strand breaks (DSBs).

PTMs:

Phosphorylated at Tyr-291 by FYN and HCK, inducing WAS effector activity after TCR engagement. Phosphorylation at Tyr-291 enhances WAS activity in promoting actin polymerization and filopodia formation.

細胞の位置付け:

Cytoplasm>Cytoskeleton. Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed predominantly in the thymus. Also found, to a much lesser extent, in the spleen.

タンパク質ファミリー:

The WH1 (Wasp homology 1) domain may bind a Pro-rich ligand.

The CRIB (Cdc42/Rac-interactive-binding) region binds to the C-terminal WH2 domain in the autoinhibited state of the protein. Binding of Rho-type GTPases to the CRIB induces a conformation change and leads to activation.

研究領域

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Bacterial > Pathogenic Escherichia coli infection.

· Human Diseases > Infectious diseases: Bacterial > Shigellosis.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

参考文献

1). MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway. Cell death & disease, 2025 (PubMed: 39863600) [IF=8.1]

Application: IF/ICC    Species: human    Sample:

Fig. 7: MAPK4 inhibits the activation of the PI3K signaling pathway in B cells of arthritis mice by activating the IRF4-SHIP1 pathway. A Western blot analysis of pSHIP1 and pIRF4 expression levels in B cells from WT and MAPK4 KO mice stimulated in vitro with sAg for 0, 5, 10, and 30 min. B Western blot analysis of SHIP1 expression in B cells from WT and MAPK4 KO mice. C Co-immunoprecipitation assay to analyze the interaction between IRF4 and MAPK4. D Western blot analysis of pIRF4, pSHIP1, pPI3K (p85), and pAKT expression levels in WT B cells stimulated in vitro with sAg for 0, 5, 10, and 30 min, with or without Vacquinol-1 treatment. Representative blots from three independent experiments are presented for all of the above. E–H Flow cytometry (E-G) and statistical (H) analysis of FO(E), T1(E), T2(E), MZ(F), and GC (G) B cell subpopulations in WT mice treated in vivo with or without Vacquinol-1 every other day for 14 days (n = 5). I–K Flow cytometry (I) and statistical analysis (J-K) of CD4 and CD8 T cells from the spleen and thymus in WT mice treated in vivo with or without Vacquinol-1 every other day for 14 days (n = 5). L, M Flow cytometric analysis of IL-10 and IL-6 expression levels in B cells from WT, CIA, and CIA mice treated in vitro with Vacquinol-1 for 1 h (n = 4). *P 

Application: WB    Species: human    Sample:

Fig. 7: MAPK4 inhibits the activation of the PI3K signaling pathway in B cells of arthritis mice by activating the IRF4-SHIP1 pathway. A Western blot analysis of pSHIP1 and pIRF4 expression levels in B cells from WT and MAPK4 KO mice stimulated in vitro with sAg for 0, 5, 10, and 30 min. B Western blot analysis of SHIP1 expression in B cells from WT and MAPK4 KO mice. C Co-immunoprecipitation assay to analyze the interaction between IRF4 and MAPK4. D Western blot analysis of pIRF4, pSHIP1, pPI3K (p85), and pAKT expression levels in WT B cells stimulated in vitro with sAg for 0, 5, 10, and 30 min, with or without Vacquinol-1 treatment. Representative blots from three independent experiments are presented for all of the above. E–H Flow cytometry (E-G) and statistical (H) analysis of FO(E), T1(E), T2(E), MZ(F), and GC (G) B cell subpopulations in WT mice treated in vivo with or without Vacquinol-1 every other day for 14 days (n = 5). I–K Flow cytometry (I) and statistical analysis (J-K) of CD4 and CD8 T cells from the spleen and thymus in WT mice treated in vivo with or without Vacquinol-1 every other day for 14 days (n = 5). L, M Flow cytometric analysis of IL-10 and IL-6 expression levels in B cells from WT, CIA, and CIA mice treated in vitro with Vacquinol-1 for 1 h (n = 4). *P 

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.